Latest Breaking News On - Marinomed biotech - Page 9 : comparemela.com

21st Austria weekly - Marinomed Austrian Post 18/12/2023 [pic1]Marinomed: Marinomed Biotech AG considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated in which the advisor will start engaging with potential partners. This initiative meets attractive market environment those assets that comply new EU medical device regulation MDR. In May 2024 important interim period ends imposing challenging requirements all devices. Products don’t fulfil these lose their certificate must not be marketed. products necessary prerequisites MDR are backed by extensive clinical data comprising >1000 patients 12 international trials. is a unique patent-protected broadly active virus-blocking compound currently used marketed product portfolio prophylaxis treatment of viral respiratory infections. Recent data also support extension using Allergy Eye

Pascal schmidtLiechtensteinische landesbankLiechtensteinischen landesbankWalter oblinMail divisionMarinomed biotechEye careSupervisory boardAustrian postManagement boardChief financial officerDeputy chief executive officerManagement board memberAustria weeklyBesuchen sieIc1 marinomed